Montpellier, France, January 12, 2016
Pursuant to the liquidity contract granted to Oddo Corporate Finance regarding Medtech shares, the following resources were listed in the liquidity account as of December 31, 2015:
- 14,052 Medtech shares
- 168,343.29 Euros
As of June 30, 2015, the most recent update, the following resources had been allocated to the liquidity account:
- 6,360 Medtech shares
- 368,737.44 Euros
Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.
In 2007, MEDTECH developed ROSA™, an innovative technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada.
In 2013 MEDTECH received the “European Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic- assistive device for minimally invasive surgery of the spine.
In November 2015, MEDTECH was honored by Deloitte In Extenso for its excellent performance in the Technology Fast 50 Mediterranean Awards, in the “listed company” category.
In 2015 MEDTECH received the “2016 Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In January 2016, MEDTECH obtained the FDA clearance for its new product, ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.
Chief Financial Officer
Tel : +33 (0)4 67 10 77 40
Tel : +33 (0)1 53 67 36 77
Alexandra Prisa (EU)
Tel. : +33(0)1 53 67 36 90
Joanna Zimmerman (US)
Tel : +1 646-536-7006
Rachat d'actions / contrat de liquidité :
- Information relative au contrat de liquidité
Full and original press release in PDF:
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|MEDTECH||Euronext Paris||50.00 (c)||0.00%||0|